Dmitry Druzhinin

Dr. Dmitry Druzhinin


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2019 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
DDDmitry Druzhinin
Dmitry Druzhinin
ЕNЕugeniia Naumova
Еugeniia Naumova
SNSergey Nikitin
Sergey Nikitin

24 April 2019 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
SNS. S. Nikitin
S. S. Nikitin
AMAysylu Murtazina
Aysylu Murtazina
DDDmitry Druzhinin
Dmitry Druzhinin
Evaluation and interpretation of electrophysiological phenomena often plays an important role in the diagnosis of neuromuscular diseases. Motor nerve conduction block is a reduction of either amplitude or area of the compound motor action potential elicited by proximal to distal motor nerve stimulation. Today, the value of conduction block in the diagnosis of demyelinating and axonal neuropathies, as well as the diagnostic criteria for these disorders, are still under discussion.Objective of the review of the literature is to highlight the value of conduction block as an electrophysiological phenomenon in the light of clinical manifestations. There is no consensus in the literature which motor response parameters should be used as partial conduction block criteria. The diversity of pathogenic forms in which conduction block can be registered does not allow to consider the phenomenon as a sign of only demyelinating lesions, and the term conduction block should be considered as a pure electrophysiological phenomenon. Different pathophysiological mechanisms of conduction block formation should be studied separately within each nosology. Conduction block detection does not allow to specify a particular diagnosis, however, in conjunction with clinical and anamnestic data, it may be the main argument in the diagnosis of a number of peripheral nerves diseases.

1 January 2020 in Burdenko's Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
DDDmitry Druzhinin
Dmitry Druzhinin
EDE.S. Druzhinina
E.S. Druzhinina
МНМ. Л. Новиков
М. Л. Новиков
ТТТ. Э. Торно
Т. Э. Торно
AKA.S. Karapetyan
A.S. Karapetyan
СНС. С. Никитин
С. С. Никитин
To describe clinical and sonographic features of confirmed intraneural perineurioma in 5 patients. We report clinical and sonographic features and retrospective follow-up data in 5 patients with intraneural perineurioma verified by biopsy. In all cases, symptoms were represented by a slowly progressive painless mononeuropathy with muscle atrophy and impaired tendon reflexes. Ultrasound examination revealed locally enlarged cross-sectional area of the nerve that was confirmed by intraoperative visualization. Intraneural perineurioma should be obligatory suspected in case of fusiform thickening of the nerve with locally changed echogenicity. Pooled multiple-center studies with large samples are needed to determine sensitivity and specificity of the main ultrasound parameters including changes in cross-sectional area and echogenicity of the nerve.

25 March 2023 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
OTO. A. Tikhonova
O. A. Tikhonova
DDDmitry Druzhinin
Dmitry Druzhinin
Anastasia TynterovaAnastasia Tynterova
Anastasia Tynterova
IRI. V. Reverchuk
I. V. Reverchuk
This review focuses on chemotherapy-induced polyneuropathy, which is a fairly common side effect and affects not only the quality of life of patients with malignancies, but can also lead to a change in patient management tactics, namely dose modification, delay of drug administration to complete cessation of treatment, which threatens the life of the patient. Chemotherapy-induced polyneuropathy is based on different mechanisms of damaging effects depending on the type of cytotoxic agent. The most neurotoxic drugs are platinum drugs, taxanes, periwinkle alkaloids, bortezomib, and thalidomide. As a result of neurotoxic effects, damage occurs to thin and thick fibers of peripheral nerves. However, it is still a mystery why one patient develops manifestations of neurotoxicity and another does not. Therefore, the modern medical community is faced with the urgent question of further study of the mechanisms of development, risk factors, as well as the search for biomarkers and the development of prevention and treatment of chemotherapy-induced polyneuropathy. The results of studies on the mechanism of onset, clinic, diagnosis, prevention and treatment of chemotherapy-induced polyneuropathies are summarized.

1 August 2023 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
LBLev Brylev
Lev Brylev
VDV. S. Demeshonok
V. S. Demeshonok
AAA. I. Ataulina
A. I. Ataulina
MKM. O. Kovalchuk
M. O. Kovalchuk
DDDmitry Druzhinin
Dmitry Druzhinin
AGA. B. Guekht
A. B. Guekht

30 April 2018 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
ENE. S. Naumova
E. S. Naumova
SNS. S. Nikitin
S. S. Nikitin
TAT. A. Adyan
T. A. Adyan
DDDmitry Druzhinin
Dmitry Druzhinin
VVV. A. Varshavskiy
V. A. Varshavskiy
The DNA analysis revealed a transthyretin amyloidosis with a rare Phe53Leu mutation in a woman of 62 y.o. with the late onset progressive generalized axonal sensomotor neuropathy, dry eye syndrome, and an episode of severe unintentionally weight loss. The same mutation was found in her healthy 34 y.o. son, but not in a 42 y.o. daughter. The Congo red staining were negative in nerve and salivar gland biopsies samples. The reassessment of the transthyretin amyloidosis “red flags” showed that the patient fulfilled the criteria of the disease and the absence of amyloid deposition was not the ground to reject the hereditary cause of the condition. The reasons of the misdiagnosis are discussed.